Table 4 Adverse Events
From: A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Toxicity | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade Not Determined |
|---|---|---|---|---|---|
No. Patients (%) N = 125 | |||||
Hematologic | |||||
Anemia | 31 (25) | 12 (10) | 1 (<1) | 0 | 6 (5) |
Leukopenia | 24 (19) | 8 (6) | 3 (2) | 1 (<1) | 6 (5) |
Neutropenia | 12 (10) | 0 | 0 | 0 | 19 (15) |
Thrombocytopenia | 14 (11) | 4 (3) | 1 (<1) | 1(<1) | 6 (5) |
Non-hematologic | |||||
Skin/hand-foot syndrome | 20 (16) | 17 (14) | 7 (6) | 1 (<1) | 2 (2) |
Pain | 22 (18) | 8 (6) | 4 (3) | 0 | 4 (3) |
Alopecia | 13 (10) | 6 (5) | - | - | 7 (6) |
Nausea | 25 (20) | 4 (3) | 0 | 0 | 3 (2) |
Stomatitis | 16 (13) | 6 (5) | 2 (2) | 0 | 5 (4) |
Vomiting | 5 (4) | 2 (2) | 1 (<1) | 0 | 4 (3) |
Diarrhea | 3 (2) | 3 (2) | 0 | 0 | 5 (4) |
Infection | 0 | 1 (<1) | 0 | 0 | 0 |
Fatigue | 0 | 0 | 1 (<1) | 0 | 0 |